VISION
Happier, healthier lives through responsible self-care

MISSION
Empower consumer self-care by preserving and expanding choice and availability of consumer healthcare products
Through leadership, determination, relationships, education, and research, we continue to grow our ability to be an effective advocate for self-care and the value of consumer healthcare products.
Rarely — if ever — has the consumer healthcare industry been so poised for growth, yet so vulnerable to further regulatory scrutiny. At such times, the value of united industry action is more clear than ever.

While CHPA made progress this year on long-standing, ingredient-specific initiatives, your association also accelerated efforts at the federal, state, and municipal levels to challenge, modify, and in some cases defeat new mandates that impact your businesses. CHPA also moved forward in 2015 with new initiatives such as expanding member education through OTC Academy, strengthening consumer education efforts by launching KnowYourOTCs.org, and improving B2B offerings via a newly formatted Meet the Manufacturer.

Notably, 2015 was a foundational year of progress in protecting and modernizing the OTC Monograph System, developing alternatives to mandatory take-back programs, and identifying tangible ways CHPA can facilitate future growth of our industry. As facilitator, counselor, and advocate, CHPA is providing vital leadership at a critical time.

**Leadership Facilitates Growth**

Excellent member engagement and collaboration, along with strong CHPA board leadership, led to the development of industry priorities for updating and modernizing the OTC Monograph System. With a deep understanding of FDA's reform priorities gleaned from ongoing dialogue among industry, FDA, and Congress, we are hopeful that important reforms can be agreed upon and enacted into law in 2016.

We also defended industry against unnecessary and burdensome legislation from activist municipalities, such as take-back programs or microbeads regulation. We contested mandatory take-back programs in California throughout 2015, and though unsuccessful in defeating them, we take forward important learnings and are better prepared to face challenges in other municipalities. In the months ahead, we aim to educate consumers about safe in-home disposal of OTC products alongside stakeholders such as pharmacists, law enforcement, senior centers, and retailers. Advocacy on this important issue requires a highly coordinated effort across multiple industry associations, and we will remain at the vanguard in providing disposal education and leadership.
Throughout the year, CHPA continued its growth initiative, grounded in 2014 research that identified those influencers of self-care that could accelerate measurable industry growth. From our insights, we developed commercial concepts to deliver momentum for the self-care movement, driving trust and value, thereby growing the OTC sector. This effort will also enable us to better serve consumers.

We’re proud of the association’s results this year, in service of our healthy and vibrant membership base – we are celebrating our highest membership level ever. We are external facing and in touch with our stakeholders and the realities of our industry, the challenges of which require a long-term commitment. We look forward to working with you to help grow our industry.

Scott Melville
CHPA President and CEO

Patrick Lockwood-Taylor
CHPA Chairman of the Board;
Vice President, Personal Health Care
North America & Digestive Wellness
Design, The Procter & Gamble Company
Leadership Delivers growth

Spearheading industry issues to lead on behalf of member companies
Leading OTC Monograph Reform

Reform of the regulatory system covering the majority of OTC medicines has been discussed and debated for many years. This year CHPA took a bold leadership position to advance toward substantive reform. CHPA members aligned around reform concepts and held a series of meetings with FDA to move closer to a mutually beneficial Monograph reform package. If we are able to move ahead, the proposals satisfy the most pressing concerns of FDA and manufacturers, and ensure continued consumer confidence in a regulatory system that has served public health well for the past four decades.

The proposals would include:

- streamlining today’s cumbersome rule-making process to one that enables faster scientific decisions on ingredient and safety issues;
- creating a pathway for innovation under Monographs; and
- ensuring a forward-looking and sustainable system in support of public health.

While discussions remain fluid, CHPA will continue to work with FDA, lawmakers, and stakeholder groups to advance the reform. Ultimately, these policies will put us all on a path toward more regulatory clarity and certainty our members need to deliver future growth.
Addressing Drug Take-Back Requirements

This year, local officials in California ramped up efforts to require drug manufacturers to develop and pay for community programs that collect and then incinerate consumers’ unwanted or expired medicines. Mandating costly and conflicting programs is entirely unnecessary. It is safe, convenient, and free for consumers to dispose of OTC medicines in their household trash.

CHPA took the lead among drug manufacturing associations to fight the spread of drug take-back mandates and educate consumers on how to safely dispose of medicines. We were the only national association on the ground fighting the spread of county mandates in the Bay Area of California, and we are working with our association partners to organize the industry’s efforts to combat a potential mandate in LA County and prevent the spread of mandates to other states.

Addressing the threat of mandates will require a coordinated industry working together with retailers, pharmacists, distributors, and other stakeholders. CHPA will remain at the forefront as we work towards developing alternatives to mandated programs that give lawmakers a more cost-effective way to support environmentally sound drug disposal.

8 in 10 consumers prefer to be educated

- We drove the research necessary to understand how consumers think about disposal in order to better educate elected officials on their constituents’ needs. For example, we learned that eight in 10 consumers prefer to be educated on in-home disposal versus sharing the cost of a mandated take-back program.

- Working with stakeholders, we educated policymakers about the science and facts regarding safe OTC disposal.

- We spearheaded consumer education on safe disposal through the CHPA Educational Foundation and through partnerships with national groups such as the American Association of Poison Control Centers and the Alliance for Aging Research.

TO FURTHER BOLSTER OUR ADVOCACY AND COMMUNICATIONS EFFORTS THIS YEAR:

- We spearheaded consumer education on safe disposal through the CHPA Educational Foundation and through partnerships with national groups such as the American Association of Poison Control Centers and the Alliance for Aging Research.

CHPA’s Carlos Gutierrez testified during a hearing on safe medicine disposal.
Restoring OTC Medicines in Tax-Preferred Accounts

CHPA led advocacy efforts to restore OTC medicines in flexible spending arrangements (FSAs) and health savings accounts (HSAs). We helped secure bipartisan, bicameral legislation — The Restoring Access to Medication Act of 2015 — in both the House of Representatives (H.R. 1270) and the U.S. Senate (S. 709).

On September 17, the legislation passed favorably out of the House Ways and Means Committee and is awaiting House Floor consideration.

ADDITIONAL HIGHLIGHTS INCLUDE:

- We mobilized constituents to send more than 50,000 letters to members of Congress in support of The Restoring Access to Medication Act of 2015.
- We collaborated with the Health Choices Coalition on media. AARP wrote and published a blog post on their website. Morning Consult ran an op-ed authored by CHPA President and CEO Scott Melville. Roll Call ran a joint op-ed authored by Scott Melville and Sjogren’s Syndrome Foundation CEO Steven Taylor.
- Working with Nielsen, CHPA promoted data that showed 75 percent of consumers prefer OTC medicines be restored in FSAs and HSAs. We also promoted new data on how the policy impacts Americans with chronic conditions treated by OTC medicines. We developed infographics to amplify these findings with policymakers and consumers.
Supporting Homeopathic Products

In response to increased scrutiny surrounding homeopathic products, CHPA underscored the safety of these products with key regulators throughout the year.

- In April, CHPA partnered with the American Association of Homeopathic Pharmacists to provide support surrounding an FDA hearing on homeopathic products. This included sponsoring an analysis of six years of data from the National Poison Data System, conducted by the Rocky Mountain Poison and Drug Center, which highlighted the strong safety profile of homeopathic medicines.

- We conducted and promoted a national consumer survey, which showed consumers strongly desire a choice of consumer healthcare options, including allopathic medicines, dietary supplements, and homeopathic products.

CHPA’s David Spangler (second from right) joined fellow industry participants during a FTC workshop on homeopathic products.

At a September Federal Trade Commission workshop, CHPA presented and raised questions about ad substantiation standards in defense of homeopathic products.
Increasing Consumer Access through Rx-to-OTC Switch

More than 700 products available today as OTC were once prescription only. Rx-to-OTC switch remains a primary driver of OTC growth, and CHPA promoted the benefits of this regulatory pathway across both domestic and global audiences.

- CHPA worked with many of our members and the World Self-Medication Industry (WSMI) on a switch advocacy tool kit to help associations around the world advocate for policies that improve access to new OTC medicines.

  This tool kit has already been used by the OTC association in Brazil, and has applicability both around the world and here in the U.S.

- Collaborating with key academic thought leaders, we initiated new research to demonstrate the benefit of access to expanded options for treating frequent heartburn. Findings will be available in the coming year.

- Recognizing switch as a global phenomenon, President and CEO Scott Melville spoke at the Asociación de Fabricantes de Medicamentos de Libre Acceso AC (AFAMELA)/WSMI international conference about the U.S. regulatory process of Rx-to-OTC switch to more than 200 attendees in Mexico City.

We will continue to be a vocal proponent of the benefits of Rx-to-OTC switch. We are awaiting a proposed rule from FDA on its “Nonprescription Safe Use Regulatory Expansion” (NSURE) initiative, designed to expand the range of programs or tools sponsors can use to assure switch candidates can be used safely and effectively by consumers.
Determination Drives growth

Advancing, shaping, and driving legislative priorities on Capitol Hill and across all 50 states
Maintaining Access to Pseudoephedrine

Working across the states, CHPA continued to provide concrete, effective solutions to ensure law-abiding consumers have access to medicines containing pseudoephedrine (PSE) without a prescription and to prevent the illegal sale of PSE.

Working with attorneys general, governors, and state lawmakers, CHPA co-hosted anti-smurfing public awareness events in Springfield, Mo. and Tulsa, Okla.

Arkansas and Montana joined the National Precursor Log Exchange (NPLEx), which blocks the illegal sale of PSE at the point of sale, in real-time, and across state lines. Now 32 states have chosen the real-time, stop-sale system over prescription-only laws. This system, created by CHPA and its members, preserves consumer choice and gives law enforcement a tool to identify potential criminal activity.

100 MEETINGS

No federal PSE-related bills were introduced, a likely result of the more than 100 meetings held by CHPA staff and members on Capitol Hill to educate lawmakers on this issue.

Eight prescription-only bills were defeated in Indiana, New York, South Carolina, and West Virginia.

ADDITIONAL HIGHLIGHTS INCLUDE:

- Secured more than 1,290 media deliverables that included our messages.
- Engaged more than 192 stakeholder groups, including the Asthma and Allergy Foundation to insert the consumer perspective into the debate.
- Launched a robust digital campaign that encouraged views of our new educational NPLEx video, while also driving traffic to StopMethNotMeds.org. During the first week the video was promoted on Facebook, it reached more than 1.1 MILLION PEOPLE.
Fighting Teen Cough Medicine Abuse

CHPA began 2015 armed with the knowledge that teen abuse of dextromethorphan (DXM) is at its lowest rate since we started tracking this behavior in 2006. This reinforced our determination to maintain these low levels of abuse through education and legislation.

- Kentucky, New Jersey, and Tennessee passed CHPA-supported legislation to stop the sale of medicines containing DXM to minors.
- Due to extensive feedback from FDA, the House of Representatives redrafted and reintroduced the DXM Abuse Prevention (DAP) Act of 2015 (H.R. 3250).
- Fourteen stakeholders wrote a joint letter to Capitol Hill, including Safe Kids Worldwide, the Community Anti-Drug Coalitions of America, D.A.R.E., and many others expressing their support of age-18 DXM purchase limits with CHPA.

Teens engaged with our digital content more than six million times, resulting in 125,000 downloads of our newest offering, the DXM Labworks app. On average, teens spent seven minutes using the app.

Through our comprehensive parent educational campaign, Stop Medicine Abuse and Five Moms, CHPA reached parents approximately 280 million times, delivering more than 479,000 engagements.

In September, we hosted a forum called “Inside the Teen Brain: Is There an App for That?” to kick off National Medicine Abuse Awareness Month. The forum brought together four experts to foster a lively conversation about reaching teens today.
Advocating for an OTC Branding Guidance

In response to FDA’s draft guidance “Best Practices in Developing Proprietary Names for Drugs,” CHPA requested a separate guidance be issued specifically on naming principles that could be applied to OTC medicines under new drug applications.

We drafted a proposed guidance for FDA review, “Guidance for Industry and Food and Drug Administration Staff, Best Practices in Developing Proprietary Names for Nonprescription Drugs.” This reinforced multiple factors impacting proprietary name selection unique to OTC medicines that would merit an alternative approach.

We will continue to work with FDA and respond to the agency’s questions as they review our proposed guidance document.

Shaping Microbeads Legislation

Synthetic plastic microbeads legislation was a particularly prominent issue in 2015. CHPA supported uniform state solutions to phase out microbeads from personal care products and OTC medicines in an orderly time frame, as opposed to a patchwork of varying state and local laws that could disrupt consumer access to important products.

CHPA proactively shaped microbeads legislation in nine states with favorable definitions and manageable phase-out dates. We also actively engaged on legislation in 12 other states and five localities, and we continue to promote bi-partisan federal legislation to ensure uniformity and acceptable phase-out dates at the state level.

WHAT ARE TEENS SEARCHING & WHO DO THEY TRUST?

1 IN 30 TEENS HAVE ABUSED OTC COUGH MEDICINE containing dextromethorphan (DXM) to get high. Teens report taking up to 25 times or more of the recommended dose.

Be aware of Erowid.com – an information-based site teens search for answers.

479,000 ENGAGEMENTS WITH PARENTS

1. What is DXM like?
2. 2 common online search queries about DXM abuse are “What is it like?” and “How do I do it?”
3. Teens are almost 3 times as likely to trust their friends as a source of information than their family.
4. Teen online search for DXM increases when they return to school in September/October and January/February.
Ensuring the Availability of Safe Dietary Supplements

With the dietary supplements category experiencing a particularly high level of scrutiny this past year, CHPA worked with its fellow supplement associations to rebut reports of an “unregulated” dietary supplements industry and to ensure the continued availability of safe dietary supplements for consumers across the country.

- The Office of Dietary Supplements’ (ODS) issued a Strategic Plan 2010-2014 Progress Report. In response, we submitted comments requesting that ODS ensure collaboration with industry on external communication and enhanced engagement with other dietary supplement trade associations.

- CHPA submitted joint comments with the Council for Responsible Nutrition encouraging FDA to pay particular attention to relevant safety standards for new dietary ingredients (reasonable expectation of safety) when providing guidance for toxicological testing (i.e., the Redbook).

- We updated the CHPA Voluntary Guideline for caffeine-containing supplements to add a new provision stipulating that members would not sell bulk powdered pure caffeine directly to consumers.

- CHPA provided support for an industry-commissioned white paper that refuted New York Attorney General Eric Schneiderman’s claims that DNA barcoding technology revealed the absence of labeled ingredients, when in fact that technology is not an appropriate test for herbal extract products.
Engaging in California Proposition 65 Activities

CHPA continued to address Proposition 65-related activities to assist our members who manufacture, distribute, and sell OTC medicines in California in remaining compliant with all applicable state regulations.

HIGHLIGHTS INCLUDE:

- We signed on to a coalition letter requesting that the Office of Environmental Health Hazard Assessment (OEHHA) vigorously defend against a lawsuit seeking to rescind the current safe harbor value for lead.

- CHPA submitted comments on OEHHA’s proposed changes to “clear and reasonable” warning regulations, including the proposed development of a consumer website for Proposition 65 chemicals. We also provided financial support for an economic impact analysis on these proposed regulations demonstrating the significant cost to industry if these proposals are passed.

- We requested clarity from OEHHA on the notice of intent to list a particular form of Aloe vera.

Working with Dr. Noel Weiss of the University of Washington, CHPA commissioned a review of evidence examining the association between acetaminophen use and cancer. The goal is to inform any future OEHHA decision regarding their designation of acetaminophen as a “high priority” chemical in 2011.
Relationships Nurture growth

Nurturing and developing relationships among regulators, policymakers, media, stakeholders, and members
Regulators

A common theme for CHPA’s regulatory activities in 2015 was collaboration. We strengthened relationships and increased dialogue around key industry issues with valuable stakeholder partners, including FDA and USP.

FDA Center for Drug Evaluation and Research (CDER) Director Janet Woodcock and The U.S. Pharmacopeial Convention (USP) President Ron Piervincenzi participated in the keynote session during CHPA’s 2015 Regulatory, Scientific & Quality Conference, alongside CHPA President and CEO Scott Melville.

CHPA held more than 20 meetings with FDA on topics including product naming, labeling, medication errors, and OTC Monograph Reform.

Collaborating with international partners on the International Conference on Harmonization (ICH), we drafted new Q12 guidelines on lifecycle management to promote innovation and strengthen quality assurance, including proactive planning of supply chain adjustments.

Through dialogue around regulatory policies including switch, we strengthened our international relationships with global partners like WSMI and AFAMELA.

Working with FDA and USP, we continued to shape and influence product quality standards so that they meet the needs of OTC businesses.
Policymakers

CHPA remained dedicated to building and strengthening relationships by educating lawmakers about key legislative priorities on Capitol Hill, across the 50 state capitals, and in local government.

- We held 150 meetings on Capitol Hill in 2015, including with 27 new members of Congress, new Committee chairs, and new staff on key Committees.

- CHPA hosted or co-hosted seven political fundraisers for incumbent members of Congress to support their reelection efforts. These events are made possible by personal contributions to the CHPA Political Action Committee (PAC) from CHPA members and association staff, as well as contributions from member company PACs.

- At the state level, we regularly met with legislative leaders, governors, and attorneys general in key states. This helped to secure passage of self-care resolutions in several states. We also gained proclamations from states recognizing National Medicine Abuse Awareness Month.

- We educated non-partisan and partisan state policy groups on key legislative issues throughout the year.

- CHPA staff participated in panels and served on the boards of policy groups. Our involvement included the Alabama Drug Task Force, the Indiana Substance Abuse and Child Safety Task Force, the Kanawha County Substance Abuse Task Force, and the Los Angeles County Product Stewardship Working Group.
Media & Stakeholders

CHPA made it a priority to develop and reinforce relationships with media professionals and stakeholder groups in 2015. We educated all parties on top association priorities, including the value of OTC medicines and dietary supplements.

Throughout the year, we quickly responded to nearly **200 media inquiries** on industry topics.

We connected with more than **20 patient advocacy organizations**, retailer associations, and other industry stakeholder groups to align priorities, including:

- Alliance for Aging Research
- American Association of Poison Control Centers
- American Cleaning Institute
- Biotechnology Industry Organization
- Council for Responsible Nutrition
- Council of State Retail Associations
- Generic Pharmaceutical Association
- Personal Care Products Council
- National Association of Chain Drug Stores
- National Community Pharmacists Association
- Pharmaceutical Research and Manufacturers of America

On social media platforms, we engaged with media and stakeholders by providing thoughtful, relevant content on industry priorities. CHPA’s Twitter followers jumped by **150 percent** and LinkedIn connections grew by more than **90 percent**.

CHPA reached out to **140 news reporters** representing trade, beltway, and national media. We helped ensure that media covered industry perspective on issues like Rx-to-OTC switch, consumer choice, and access to OTC medicines. CHPA was a source for article development, testimonials, and background on industry practices. We placed stories in outlets including *The Boston Globe*, *Politico*, and *The San Francisco Examiner*.
CHPA Members

A myriad of CHPA events provided members with relationship-building opportunities all year long.

In 2015, CHPA welcomed 25 new members, including six manufacturer and 19 associate members.

Market Exchange allowed members to meet one-on-one during a comprehensive, one-day networking forum.

The Annual Executive Conference provided networking and educational opportunities for more than 400 senior-level executives over three full days.

Retail Immersion with CVS Health provided a unique opportunity for CHPA members to hear from CVS Health’s leadership team and network to develop successful retailer-manufacturer collaborations.
President’s Forum provided an intimate community for CEO-level member executives from mid-cap manufacturer companies to meet exclusively with key retailers.

Meet the Manufacturer provided an informative and casual dialogue for associate members and contract/private label manufacturers to meet with Bayer HealthCare and Valeant Consumer Health Care executives. Discussion focused on how to better partner with them for mutual success.

The Regulatory, Scientific & Quality Conference allowed nearly 275 members to network with and learn from academic experts and regulators, including FDA and USP representatives.
Education Fosters Growth

Fostering a knowledgeable industry community through educational opportunities
Bolstering Education with OTC Academy

In June, CHPA launched a new educational brand for the association and a go-to source for professional education on the consumer healthcare industry. Designed to expand and grow the knowledge of industry professionals, OTC Academy provides a comprehensive overview of business-critical topics through three different learning formats: e-learning, seminars, and workshops. The academy’s curriculum allows industry professionals to stay up-to-date on relevant industry topics, while providing them with resources to thrive in today’s marketplace.

We offered seven programs for members and non-members through OTC Academy:

- **Six webinars** on homeopathy, USP, hazardous waste, game-changing legislation, child-resistant packaging, and OTC shopper insights
- **A new seminar** called “OTC 101,” providing introductory information on the OTC industry

Collectively, CHPA’s OTC Academy educated more than 750 consumer healthcare professionals from 90 companies.

750+ members

Collectively, CHPA’s OTC Academy educated more than 750 consumer healthcare professionals from 90 companies in 2015.
Accelerating Growth at the Annual Executive Conference

More than 400 senior-level executives convened in Bonita Springs, Fla., March 9-11 for CHPA's 2015 Annual Executive Conference. Attendees explored how to seize the opportunities in today's dynamic healthcare environment to accelerate growth. No session was more apt to encourage dialogue about accelerating growth than “Self-Care: The Year of the Deal,” which focused on mergers and acquisitions in the consumer healthcare industry. With M&A deals topping $200 billion in 2014, industry experts discussed the rationale, structures, and valuations behind deal-making and maximizing growth potential in the industry.

Learning from FDA at the Regulatory, Scientific & Quality Conference

Hundreds of professionals from across the country came to Washington, D.C., May 14-15 for CHPA's 2015 Regulatory, Scientific & Quality (RSQ) Conference. Attendees from FDA, USP, industry, and academia engaged during a two-day, comprehensive business program focused on the latest regulatory, scientific, and product quality topics impacting the consumer healthcare products industry. More than 40 FDA representatives attended, allowing attendees the opportunity to talk one-on-one about industry priorities. FDA also spoke on several panels about initiatives impacting the current and future state of OTC medicines, including FDA Monograph modernization and the Safe Use Initiative.
Empowering Consumers through the CHPA Educational Foundation

This year, the CHPA Educational Foundation developed and launched a new consumer brand, KnowYourOTCs.org. As consumers take on more responsibility for their own healthcare, they need clear, credible information about self-care options. KnowYourOTCs.org provides that information and helps consumers understand how to safely use, store, and dispose of OTC medicines. It delivers the information to consumers in clear, simple language and an easy-to-navigate site.

In conjunction with these exciting changes, the foundation this year continued to educate consumers across the country on appropriate use, storage, and disposal. The foundation connected with consumers in the areas of pediatric cough and cold safety through Treat with Care; safe storage through Up and Away and Out of Sight; acetaminophen safety through Know Your Dose; and safe medicine disposal through its educational projects with the Alliance for Aging Research and the American Association of Poison Control Centers.

For more information on the foundation’s 2015 performance, make sure to read the 2015 CHPA Educational Foundation Annual Report.
Research Cultivates growth

Exploring and cultivating new research avenues to support industry initiatives
Developing Messages that Increase Consumer Trust in OTC Medicines

Building on the industry growth research completed in 2014, CHPA embarked on a new research project that aimed to determine whether an industry-wide communications campaign could successfully enhance consumer trust in OTC medicines. Having previously identified a “trust gap,” we developed messages and creative to address a segment of consumers who lack confidence in the safety and effectiveness of OTC medicines. Over the course of six months, CHPA formed a member working group, secured advertising and research partners, and completed creative development and testing.

- We identified creative concepts that effectively increased confidence in OTC medicines, including increased consideration and purchase intent.

- The messages that resonated the most with consumers included OTC medicines’ prescription heritage and the doctor’s endorsement of OTC medicines.

- CHPA is working with members to leverage these messages in consumer outreach.

- 700+ over-the-counter (OTC) products available today were once prescription only. Before allowing this switch, the FDA requires high levels of safety and effectiveness.
Advancing Awareness through Research on Pediatric Cough and Cold Products

CHPA continued its commitment to further the scientific knowledge around ingredients commonly found in children’s cough and cold products. We made progress on our ongoing clinical research for three ingredients: dextromethorphan, guaifenesin, and pseudoephedrine. We also funded research with the Rocky Mountain Poison and Drug Center, which shows that adverse events continue to decline for combination products.

Key stakeholder partners also continued to explore trends in the safe use of pediatric cough and cold products. *Pediatrics*, the official journal of the American Academy of Pediatrics, published a study in September citing government data that showed the number of emergency department (ED) visits for unsupervised medication exposures in young children, on the rise since 2004, peaked in 2010 and has been steadily declining since. This decrease reinforces that industry’s voluntary labeling and packaging efforts, as well as CHPA’s educational partnerships, are keeping kids safe.

Emergency department visits for unsupervised medication exposures in young children have been steadily declining since 2010.

The educational campaign Up and Away and Out of Sight, a collaboration between the CHPA Educational Foundation and the U.S. Centers for Disease Control and Prevention’s PROTECT Initiative, aims to prevent accidental, unsupervised ingestion of medicines by young children by reminding parents to store medicines up and away and out of children’s reach and sight every time they are used. See more information about Up and Away efforts in the 2015 CHPA Educational Foundation Annual Report.
CHPA Board of Directors

Patrick Lockwood-Taylor (Chair)
Vice President, Personal Health Care North America & Digestive Wellness Design
The Procter & Gamble Company

Christopher D. DeWolf (Immediate Past Chair)
President & Chief Executive Officer Lil’ Drug Store Products, Inc.

Christopher B. Ascher
Co - President B.F. Ascher & Company, Inc.

Natalie Bartner
President, Consumer Care North America Bayer HealthCare LLC

J.P. Borneman, Ph.D.
Chairman & Chief Executive Officer Hyland’s, Inc.

Daniel R. Chiazza
Senior Vice President, Nielsen Consumer Insights, North America Nielsen

Jorge Daboub
Senior Vice President, Business Development Univision Communications Inc.

Julie Dillon
General Manager, Professional Oral Care, NA, Oral Pharmaceuticals Colgate-Palmolive Company

Michael J. Donnantuono
President & Chief Operating Officer Blistex Inc.

Gary R. Downing
Chief Executive Officer Clarion Brands, LLC

Scott R. Emerson
Partner NUMARK Brands

Mike Fogarty
Executive Vice President, Consumer Sales and Marketing WebMD

John J. Francis
Vice President, OTC Sales & Marketing, NA Taro Pharmaceuticals U.S.A., Inc.

Jeffery H. Gerchenson
Chairman & Chief Executive Officer Alva-Amco Pharmacal Companies, Inc.

Joseph F. Gordon
General Manager Valeant Consumer Health Care

John C. Incledon
President & Chief Executive Officer, Hisamitsu America, Inc. Hisamitsu Pharmaceutical Co., Inc.

Milan K. Kalawadia
Vice President, Head of U.S. OTC Dr. Reddy’s Laboratories, Inc.

Alexander Lacik
President, North America RB
CHPA Board of Directors Continued

Steven R. LaMonte
Chairman of the Board
Fleet Laboratories

Ronald M. Lombardi
President and CEO
Prestige Brands Holdings, Inc.

Robert Long
President
Chattem, Inc.

Colin I. Mackenzie
Area General Manager, North America Consumer Healthcare
GSK Consumer Healthcare

Jeffrey R. Needham
Executive Vice President and General Manager, U.S. Consumer Healthcare
Perrigo Company

Ryan Olohan
National Industry Director, Healthcare
Google, Inc.

Marc L. Rovner
Vice President & General Manager, Consumer Health Care USA
Boehringer Ingelheim Pharmaceuticals, Inc.

Akshay A. Shetty
Co-Chief Executive Officer
Combe Incorporated

Wendy Shusko
President and CEO
WellSpring Pharmaceutical Corporation

Mitchell Singer
Chief Executive Officer
PL Developments

Christopher B. Slager
Regional President, North America
Pfizer Consumer Healthcare

Randy M. Sloan
President and Chief Executive Officer
Lornamead, Inc.

Marylou Walker
Chief Executive Officer
Matrixx Initiatives, Inc.

Neill B. Walsdorf, Jr.
President
Mission Pharmacal Company

Kathleen Widmer
Co-chair, North America; President, McNeil Consumer Healthcare Division
Johnson & Johnson Consumer Inc.

Steven B. Woolf
Executive Vice President & Chief Financial Officer
Humco Holding Group, Inc.

Akiyoshi Yoshida, Ph.D.
President and Chief Executive Officer
The Mentholatum Company

Richard Zulman
Chief Executive Officer
BestCo Inc.
CHPA Senior Management Team

Scott M. Melville  
President and CEO

Brian P. Green  
Vice President, Finance and Operations & Chief Financial Officer

John F. Gay  
Vice President, Government Affairs

Barbara A. Kochanowski, Ph.D.  
Vice President, Regulatory & Scientific Affairs

Theodore L. Peterson  
Vice President, Corporate Development

Emily E. Skor  
Vice President, Communications and Executive Director, CHPA Educational Foundation

David C. Spangler, Esq.  
Senior Vice President, Policy, and General Counsel & Secretary
Upcoming 2016 CHPA Major Meetings and Events

Annual Executive Conference
March 14-16
Turnberry Isle Miami I Aventura, FL
chpa.org/AEC

Regulatory, Scientific & Quality Conference
May 19-20
Bethesda North Marriott Hotel I Bethesda, MD
chpa.org/RSQ

Meet the Manufacturer
September 14
Hyatt Regency Princeton I Princeton, NJ
chpa.org/MTM

Market Exchange
September 14-15
Hyatt Regency Princeton I Princeton, NJ
chpa.org/MX

CHPA Educational Foundation Gala
November 14
Rainbow Room I New York, NY
chpa.org/foundationgala
We invite you to learn more at chpa.org